Ondansetron Hydrochloride Injection

This product is a potent, highly selective 5-HT3 receptor antagonist with a strong antiemetic effect. Chemotherapy drugs and radiotherapy can cause the small intestine to release 5-HT, which activates the afferent branch of the vagus nerve through the 5-HT3 receptor and triggers the vomiting reflex. This product can block the triggering of this reflex. Excitation of the afferent branch of the vagus nerve can also cause the release of 5-HT in the Postrema area at the bottom of the fourth ventricle, thereby enhancing it through a central mechanism. This product is effective for nausea and vomiting caused by chemotherapy and radiotherapy, so this product exerts its antiemetic effect by antagonizing the 5-HT receptors of neurons located in the peripheral and central nervous systems. The mechanism of action of postoperative nausea and vomiting is unclear, but it may be induced by a common pathway similar to nausea and vomiting caused by cytotoxic drugs. This product can also inhibit nausea induced by opioids, and its effect

The main ingredient of this product is ondansetron hydrochloride, and its chemical name is 1,2,3,9-tetrahydro-9-methyl-3-[(2-methylimidazol-1-yl)methyl]-4-oxocarbazole hydrochloride.

This product is a colorless clear liquid.

Antiemetic. Indicated for: 1. Nausea and vomiting caused by cytotoxic chemotherapy and radiotherapy. 2. Prevention and treatment of postoperative nausea and vomiting.

This product is administered by intravenous or intramuscular injection, and the dosage can be flexibly controlled. 1. Vomiting caused by chemotherapy: The dosage and route of use should be determined according to the severity of nausea and vomiting caused by chemotherapy and radiotherapy. (1) Adults: ① For vomiting caused by highly emetic chemotherapy drugs: inject 8 mg of ondansetron injection into a vein 15 minutes before chemotherapy, 4 hours and 8 hours after chemotherapy, and take 8 mg of ondansetron tablets orally every 8 to 12 hours after stopping chemotherapy for 5 consecutive days. ② For vomiting caused by chemotherapy drugs that are not too emetic: inject 8 mg of ondansetron injection into a vein 15 minutes before chemotherapy, and take 8 mg of ondansetron tablets orally every 8 to 12 hours thereafter.

There may be headache, abdominal discomfort, constipation, dry mouth, rash, occasional bronchial asthma or allergic reactions, and transient asymptomatic increase in transaminase. The above reactions are mild and do not require special treatment. There are rare reports of movement disorders, epileptic seizures, chest pain, arrhythmia, hypotension, and bradycardia.

It is contraindicated for those who are allergic to this product. It is contraindicated for those who have gastrointestinal obstruction.

Precautions for children: Not yet determined. Precautions for pregnancy and lactation: The safety of this product during human pregnancy has not been determined. Animal studies have not shown direct or indirect harm to the embryonic, fetal, pregnancy, perinatal and postpartum periods. However, since animal studies cannot fully predict human reactions, it is not recommended for use during pregnancy, especially in the first 3 months. Experiments have shown that this product can be secreted in the milk of lactating animals, so breastfeeding should be suspended when using this product. Precautions for the elderly: Not yet determined.

1 There is no evidence that this product will induce or inhibit the metabolism of other drugs taken at the same time. Special studies have shown that this product has no interaction with alcohol, temazepam, furosemide, tramadol and propofol. 2 Patients with poor metabolism of separteine and isoquine have no effect on the elimination half-life of this product. After repeated administration to such patients, the drug exposure level is no different from that of normal humans, so the dosage and frequency of administration do not need to be changed. 3 Combination with dexamethasone can enhance the antiemetic effect. 4 It is compatible with the following intravenous fluids: 0.9% W/V sodium chloride intravenous solution (British Pharmacopoeia); 5% w/v glucose intravenous solution (British Pharmacopoeia); 10% w/v mannose intravenous solution (British Pharmacopoeia); Green's intravenous

Store below 30℃ away from light. Valid for 3 years.

2ml:4mg (calculated as C18H19N3O)

36 months

PKU HealthCare Corp., Ltd.

• Founded in:

  1993-05-18

• Address:

  No. 21, Fangzheng Avenue, Shuitu Town, Beibei District, Chongqing

• Tax NO.:

  91500000450533779H

• Registered Funds:

  595.987425 yuan

• Website:

  Log in to view

• Email:

  Log in to view